A highly selective reversible inhibitor of monoamine oxidase type A.
|Storage||Store at RT|
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
|Solvent||Max Conc. mg/mL||Max Conc. mM|
|water||16.12||50mM with gentle warming|
Preparing Stock Solutions
The following data is based on the product molecular weight 322.42. Batch specific molecular weights may vary from batch to batch due to solvent of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||3.1 mL||15.51 mL||31.02 mL|
|5 mM||0.62 mL||3.1 mL||6.2 mL|
|10 mM||0.31 mL||1.55 mL||3.1 mL|
|50 mM||0.06 mL||0.31 mL||0.62 mL|
The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.
References are publications that support the products' biological activity.
Mashkovsky and Andreeva (1981) Pharmacological properties of 2,3,3α,4,5,6-hexahydro-8-methyl-1H-pyrazino[3,2,1-j,k]carbazole hydrochloride (pirlindole), a new antidepressant. Arzneim.-Forsch.Drug Res. 31 75 PMID: 7194096
Medvedev et al (1992) Efficacy of pirlindole, a highly selective reversible inhibitor of monoamine oxidase type A in the prevention of experimentally induced epiletic seizures. Drug Investigation. 4 501 PMID:
If you know of a relevant reference for Pirlindole mesylate, please let us know.
View Related Products by Target
View Related Products by Product Action
Keywords: MAO-A inhibitors inhibits MAO Monoamine Oxygenases Oxidases Monoamine Oxidase
Citations for Pirlindole mesylate
Citations are publications that use Tocris products.
Currently there are no citations for Pirlindole mesylate. Do you know of a great paper that uses Pirlindole mesylate from Tocris? If so please let us know.
Literature in this Area
The key feature of drug addiction is the inability to stop using a drug despite clear evidence of harm. This poster describes the brain circuits associated with addiction, and provides an overview of the main classes of addictive drugs and the neurotransmitter systems that they target.
Major depressive disorder is characterized by depressed mood and a loss of interest and/or pleasure. Updated in 2015 this poster highlights presynaptic and postsynaptic targets for the potential treatment of major depressive disorder, as well as outlining the pharmacology of currently approved antidepressant drugs.
Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.